Healthcare
Live Price
Offline$50.84
+4.20% today
1Y Change
-20.30%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tempus AI, Inc. (TEM) is a Healthcare stock with a market cap of $9.59B and listed on NASDAQ. The stock last traded around $50.84 and down 20.3% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +83.4%, EPS growth of +69.3%, a dividend yield of 0.0%. What stands out right now is revenue +83.4%, EPS +69.3%, free cash flow -13.2% with operating margin -18.8% and ROIC -10.3%. Valuation sits in the middle of the pack at price/sales 7.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TEM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TEM
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TEM Max Drawdown
-58.96%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TEM and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.3B
+83.4% YoY
FY Net Income
-$245.0M
+65.3% YoY
Free Cash Flow
-$245.4M
-16.2% YoY
Revenue Growth
+83.4%
EPS Growth
+69.3%
Gross Margin
69.6%
Net Margin
-19.3%
Income statement
USD
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | 258M | 321M | 532M | 693M | 1.3B |
| Gross Profit | 84M | 130M | 286M | 381M | 798M |
| Operating Income | -244M | -265M | -196M | -691M | -253M |
| EBITDA | -220M | -237M | -133M | -610M | -106M |
| Net Income | -259M | -290M | -214M | -706M | -245M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | 278M | 303M | 166M | 341M | 605M |
| Total Assets | 531M | 631M | 564M | 926M | 2.3B |
| Total Liabilities | 1.3B | 1.8B | 1.9B | 870M | 1.8B |
| Shareholder Equity | — | — | — | — | — |
| Total Debt | 239M | 433M | 488M | 468M | 1.3B |
| Net Debt | — | — | — | — | — |
Cash flow positioning
2026 Full Year
Operating Cash Flow
226M
-14.6% YoY
Capital Expenditures
—
Free Cash Flow
245M
-16.2% YoY
Key ratios
Gross Margin
69.6%
Operating Margin
-18.8%
Net Margin
-19.3%
ROE
-59.9%
Debt / Equity
1.66x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.